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Abstract
Background: Oral lichen planus (OLP) is a premalignant mucocutaneous disease in which genetic factors and
immune responses play a major role. Cytokines play an important role in the pathogenesis and disease progression
of OLP. The aim of this study was to investigate the impact of gene polymorphisms of T helper cell subtype Th1 and
Th2 cytokines, interferon-gamma (IFN-γ), interleukin-6 (IL-6) and transforming growth factor (TGF)-β1 on OLP
susceptibility in a Saudi cohort.
Methods: Forty two unrelated patients with OLP and 195 healthy controls were genotyped for IFN-γ (874A/T),
IL-6 (174G/C) and TGF-β1 (509C/T) polymorphisms.
Results: The frequency of genotype AT of IFN-γ (874A/T) was significantly higher while genotype AA was lower in
OLP patients as compared to controls (P < 0.05). The frequency of T containing genotypes (AT + TT) was also higher in
OLP patients as compared to that in controls (P = 0.003). The frequencies of allele T was higher while that of allele A
lower in patients than the controls however the difference was not statistically significant (P = 0.07). There was no
significant difference in the frequencies of alleles and genotypes of IL-6 (174G/C) and TGF-β1 (509C/T) polymorphisms
between patient and control groups. These results indicated that genotype AT of IFN-γ (874A/T) polymorphism is
associated with OLP risk and genotype AA is protective to OLP. On the other hand the polymorphisms IL-6 (174G/C)
and TGF-β1 (509C/T) may not be associated with OLP risk in our population.
Conclusion: It is concluded that IFN-γ (874A/T) polymorphism is associated with the susceptibility of OLP, however further
studies with large sample size involving different ethnic populations should be conducted to strengthen our results.
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Background
Oral lichen planus (OLP) is a premalignant mucocutane-
ous disease in which genetic factors and immune responses
play a major role. It is a chronic inflammatory, prototype
of oral lichenoid lesions characterized by T-cell mediated
immune response and abnormal epithelial keratinization
cycle in which Th1 is considered to play a predominant
role [1–4]. The OLP lesions may coexist with cutaneous
and genital lesions, or may be the only disease manifesta-
tions. The OLP with complex pathogenesis, involves anti-
gen presentation by the oral keratinocytes either of an
exogenous or an endogenous origin [5]. This immune re-
sponse is accompanied by a mixed inflammatory response
of T-cells, macrophages, and mast cells, together with the
associated cytokines and cytotoxic molecules [5, 6]. OLP is
more common in middle aged women [7]. The genetic fac-
tors influencing immune function have been indicated to
contribute to the OLP etiology [4, 8]. Cytokines play an im-
portant role in the progression/ pathogenesis of OLP and
polymorphisms in cytokines genes such as IFN-γ, TNF-α,
TNF-β, IL-4, IL-10 have been associated with the suscepti-
bility of OLP [9, 10].
Interferon gamma (IFN-γ), a proinflammatory cytokine
has also been reported to play an important role in host
defense and immune regulation. The gene encoding
IFN-γ is located on chromosome 12q24 and consists of
four exons with three intervening regions [11]. A poly-
morphism in the first intron of IFN-γ gene at position
874 (rs2430561) directly influences IFN-γ production
level [12]. The IFN-γ (874 A/T) is located within a puta-
tive nuclear factor-kB (NF-kB) binding site, and T allele
might be responsible for the induction of IFN-γ produc-
tion at a higher level.
Interleukin -6 (IL-6) is one of the major inflammation
related cytokines [13]. It is responsible for the synthesis
of acute-phase reactants by the liver and regulates in-
flammatory/ immune pathways, bone metabolism and
endocrine functions. The human IL-6 gene is located on
chromosome 7p21. Among the polymorphic sites de-
scribed in the IL-6 gene promoter, two biallelic polymor-
phisms, 572G/C (rs1800796) and −174G/C (rs1800795)
have been associated with differences in cytokine produc-
tion. These polymorphisms consist of a single nucleotide
change from guanine (G) to cytosine (C) at positions −572
and −174 in the promoter region, respectively [14, 15].
Some researchers have investigated a possible association
between IL-6 (−174G/C) polymorphism and OLP in
Taiwanese and Brazilian patients [16, 17].
Another cytokine, transforming growth factor (TGF)-
β1 is produced by both immune and non-immune cells
and exhibits a broad range of functions including tissue
repair and immune response [18]. The TGF-β1 gene is
located on chromosome 19q13 [19] and its production is
under genetic control [20]. TGF-β1 gene polymorphisms
at codon 10 and 25 regulate the TGF-β1 production in
vivo and in vitro [21]. The most thoroughly studied
TGF-β1 (509C/T) polymorphism (rs1800469) is located
within a Yin-Yang1 consensus binding site [22] and T al-
lele has been associated with increased level of TGF-β1
in plasma [20] and reduced T cell proliferation [21].
The cytokines involved in inflammation- and immune
regulation has been suggested to play an important role
in the pathogenesis of OLP. The genotype frequencies of
polymorphisms are known to vary according to race or
ethnicity. To date, no studies have been performed in
Saudi Arabian patients to evaluate whether the IL-6,
IFN-γ and TGF- β1 gene polymorphisms are associated
with OLP susceptibility. We evaluated the association of
IFN-γ (874A/T), IL-6 (174G/C) and TGF-β1 (509C/T)
polymorphisms with OLP risk in Saudi patients.
Methods
Two hundred thirty seven Saudi subjects visiting Prince
Sultan Military Medical City (PSMMC), Riyadh Saudi
Arabia were recruited for this study. Forty two unrelated
OLP patients (16 male, 26 female) aged 27–72 years and
195 unrelated healthy matched controls from the same
ethnicity (100 male, 95 female) aged 20–65 years were
genotyped for polymorphisms in IFN-γ and TGF- β1
and IL-6 genes. Patients and controls with the history of
any other inflammatory/ autoimmune diseases were ex-
cluded from the study. The study protocol was approved
by the research and ethical committee of PSMMC,
Riyadh and written informed consent was obtained from
each subject before recruitment.
The diagnosis of OLP was based on the clinical mani-
festations and histopathological criteria of the World
Health Organization. Senior oral pathologists examined
the patients, reviewed histological findings and the pa-
tients history to diagnose OLP as described elsewhere
[9]. The patient suspected to have drug or restoration
related lichenoid lesions, and with any histologic signs of
dysplasia were excluded.
PCR amplification
Genomic DNA was extracted from the peripheral blood
samples of OLP patients and controls using QIAampR
DNA mini kit (Qiagen Hilden, Germany). IFN-γ gene was
amplified using amplification refractory mutation systems
(ARMS)-PCR methodology to detect polymorphisms at
position 874 of IFN-γ. DNA was amplified in two different
PCRs with a generic antisense primer and one of the two
allele specific sense primers (antisense: 5’- TCA ACA
AAG CTG ATA CTC CA-3’ T- allele: 5’- TTC TTA CAA
CAC AAA ATC AAA TCT-3’ and A-allele: 5’- TTC TTA
CAA CAC AAA ATC AAA TCA-3’). For quality control
and to check the success of PCR amplification in both the
reactions, an internal control of 426 bp was amplified
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using a pair of primers for the human growth hormone
(HGH). PCR amplification was carried out using 5×
FIREPol Master Mix (Solis Biodyne, Tartu, Estonia)
with specific optimized reaction conditions. The ampli-
fied products were separated on the 1.5 % agarose gel,
stained with ethidium bromide and photographed.
IL-6 (174 G/C) polymorphism was detected by PCR-
RFLP technique using a set of forward and reverse
primers [23]. Amplification of genomic DNA using spe-
cific protocol yielded a198 bp DNA. The PCR product
(198 bp) DNA was digested with SfaNI restriction en-
zyme (New England BioLabs, Beverly, MA) at 37 ° C for
3 h. Resulting into two fragment of 140 and 58 bp indicat-
ing GG genotype, while three fragment of 198, 140 and
58 bp indicating GC genotype. Undigested single band of
198 bp indicated CC genotype. The amplified products
and digested products for various samples were separated
on the 2.5 % agarose gel, stained with ethidium bromide
and photographed.
Genotyping for TGF-β1 (509C/T) polymorphisms was
performed using PCR-RFLP technique. Amplification of
a TGF-β1 using specific primers was performed to get
441 bp PCR product which was digested with restriction
enzyme Bsu36 I to get two fragments of 251 and 190 bp
for CC, three fragments of 441,251 and 190 bp for CT
and uncut DNA of 441 bp for TT genotype. The alleles
and genotypes frequencies were calculated in patients
and control groups. Hardy-Weinberg equilibrium was
determined as described earlier [9].
Statistical analysis
The differences in allele/genotype frequencies be-
tween patient and control groups were analyzed by
the Fisher’s exact test using the CalcFisher software
(www.jstatsoft.org/article/view/V008i21/Article-JSS).
P values ≤ 0.05 were considered significant. The odd ratio
interpreted as relative risk (RR) was calculated following
the Woolf ’s method as out lined by Schallreuter et al. [24].
Etiologic fraction (EF) indicating the hypothetical genetic
component of the disease and preventive fraction (PF)
showing the hypothetical protective effect of one specific
allele/ genotype for the disease were calculated using for-
mulas given by Svejgaard [25].
Results
The genotype and allele frequencies of IFN-γ (874A/T),
IL-6(174G/C) and TGF-β1 (509C/T) polymorphisms are
presented in (Tables 1, 2 and 3). The representative gel
pictures of amplification or after restriction enzyme di-
gestion for IFN-γ, IL-6 and TGF-β1 are shown in Figs. 1,
2 and 3. The results of the genotyping repeated for 30 %
of the random blind sample were compared with 100 %
success rate. The genotype distributions were in Hardy-
Weinberg equilibrium in both, OLP patient and control
groups.
The frequencies of genotypes and alleles of IFN-γ
(874A/T) polymorphism differed in OLP patients and
controls (Table 1). The frequency of heterozygous geno-
type (AT) of IFN-γ was significantly higher in OLP pa-
tients than control (P = 0.04) whereas the frequency of
homozygous genotypes (AA) was significantly lower in
OLP patients than controls (P = 0.003). The frequency of
T-containing genotypes (AT + TT) were significantly
higher in OLP patients as compared to that in controls
[P = 0.003 and relative risk (RR) = 6.712]. The frequency
of allele T was higher and that of allele-A was lower in
OLP patients than control subjects however, the difference
was slightly short of significant (P = 0.07). On the other
hand the difference in frequency of TT genotype among
the two groups was not statistically significant (P = 0.71).
The genotype and allele frequencies of IL-6 (174G/C)
polymorphism did not differ between patients and con-
trols (Table 2). Both the homozygous genotypes CC and
GG were absent in OLP patients. The heterozygous
genotype GC was present in all OLP patients while
98.98 % of the controls had this genotype. The frequen-
cies of allele G and C were exactly similar in controls
and OLP patients.
The distribution of frequencies of alleles and genotype
of TGF-β1 (509C/T) polymorphism did not differ
Table 1 Genotype and allele frequencies of IFN-γ (874A/T)
polymorphism in OLP patients and matched controls
Genotypes/
Allele
OLP (N = 42) Control (N = 195) P- value RR EFb/PF
N % N %
AA 2 4.76 49 25.13 0.003a 0.149 0.182
AT 27 64.29 91 46.66 0.04a 2.057 0.117b
TT 13 30.95 55 28.21 0.71 1.141 0.023b
AT + TT 40 95.24 146 74.87 0.003a 6.712 0.183b
A-allele 31 36.90 189 48.46 0.07 0.622 0.070
T-allele 53 63.10 201 51.54 0.07 1.607 0.078b




Table 2 Allele and genotype frequencies of IL-6 (174G/C)
polymorphism in oral lichen planus and controls
Genotype/Allele OLP (N = 42) Control (N = 195) P-value
N % N %
GG 0 0 1 0.51 0.99
GC 42 100 193 98.98 0.99
CC 0 0 1 0.51 0.99
G-allele 42 50 195 50 0.99
C-allele 42 50 195 50 0.99
N number of subjects
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significantly between OLP patients and healthy controls
(Table 3). The frequencies of genotypes CC, CT and AA
were 26.19, 64.29 and 9.52 % in OLP patients as compared
to 20.51, 58.98 and 20.51 in controls respectively. The dis-
tribution of allele C and T was quite similar, and it was re-
spectively 58.33 and 41.67 % in OLP patient group and
50 % each in healthy control group (P > 0.05).
The frequency distribution of genotypes of IFN-γ
(874A/T) polymorphism in various healthy ethnic popu-
lations is summarized in Table 4 which clearly indicated
ethnic variations.
Discussion
Genotyping results of IFN- γ (874A/T) polymorphism
indicated that T-containing genotypes are significantly
associated with the susceptibility to OLP in Saudis
(RR = 6.712). The IFN-γ is an important predominant
cytokine in the pathogenesis of OLP. The role of
IFN-γ gene polymorphism on OLP susceptibility has
been investigated in various populations. Studies from
China, Thailand and Italy indicted an association between
IFN-γ (874A/T) polymorphism and OLP [26–28] and it
has been suggested that IFN-γ (874A/T) polymorphism
may be a risk factor to OLP development.
Carrozzo et al. [26] found significant increase in num-
ber of TT homozygous genotype of IFN-γ (874A/T)
polymorphism in OLP patients compared with controls
and suggested that IFN-γ genetic polymorphism may be
an important risk factor to develop OLP in Italian. Bai et
al. [27] suggested that IFN-γ (874A/T) polymorphism is
associated with susceptibility and influence progression
of OLP in a Chinese cohort. Recently Kimkong et al.
[28] also reported an association between IFN-γ (874A/
T) polymorphism and susceptibility to OLP in Thai
population and suggested that the T allele is significantly
associated with an increased risk of OLP development as
compared to the A allele. Several other studies have also
shown that IFN-γ +874 T/A polymorphism is associated
with the development of several autoimmune diseases
while others showed no such associations [29]. These
disparities are probably caused by small sample sizes,
low statistical power, ethnic difference, and/or clinical
heterogeneity as suggested by Lee and Bae [29].
The results of present study on the associations of the
IFN-γ 874 T/A polymorphism with OLP are consistent
with the functional effect of the IFN-γ 874 T/A poly-
morphism as genotypes of the IFN-γ 874 T/A poly-
morphism have been associated with low (AA), medium
(AT), and high (TT) cytokine production [12]. The IFN-
γ 874 T/A polymorphism has been associated with auto-
immune diseases in Caucasian, Latin American, and
Middle Eastern, but not Asian, populations as shown in
a recent meta-analysis [29]. The reason why a particular
polymorphism was found to be associated with one
population and not another may be due to ethnic differ-
ences in the frequency of IFN-γ 874 T/A polymorphism
among these ethnic groups. The frequency distribution
of genotypes of IFN-γ (874A/T) polymorphism in
Table 3 Allele and genotype frequencies of TGF-β1 (509C/T)
polymorphism in OLP and controls
Genotype/allele OLP (N = 42) Control (N = 195) P-value
N % N %
CC 11 26.19 40 20.51 0.41
CT 27 64.29 115 58.98 0.60
TT 4 9.52 40 20.51 0.12
C-containing 38 90.48 155 79.49 0.12
C-allele 49 58.33 195 50 0.18
T-allele 35 41.67 195 50 0.18
N number of subjects
Fig. 1 Shows the amplification of IFN-γ (874A/T) genotypes (TT, TA and AA). Lane M: 100 bp DNA marker, Lane 1 and 3: amplification of allele T,
Lane 2 and 6: amplification of allele A (taking both alleles together: lanes 1 and 2 indicate TA genotype, lanes 3 and 4, TT genotype and lanes 5
and 6 AA genotype), 265 bp band for target DNA, 426 bp band for internal control
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various healthy ethnic populations clearly indicated eth-
nic variations (Table 4). The frequency of AA genotype
varies from 1.60 % in German to 83.51 % in Japanese
while frequency of AT genotype from 16.49 % in Japanese
to 66.22 % in Polish population. On the other hand the
frequency of TT genotype varies from 0.78 % in Chinese
to 74.15 % in German healthy population however it was
totally absent in Japanese healthy population. Obviously,
there is a difference in the frequency of the T allele of the
polymorphism among the healthy ethnic groups. The T
allele was a minor allele in Asian populations, whereas it
was a major allele in Caucasian and Latin American popu-
lations [29]. Our previous study dealing with the polymor-
phisms of pro- and anti-inflammatory cytokines showed
that the OLP patients has significantly higher frequency of
the A allele of TNF-α (−308) polymorphism [9]. Notably,
both the polymorphisms (IFN-γ and TNF-α are known to
increase the production of the respective cytokine
[30, 31]. Significantly, several studies demonstrate a
high level of IFN-γ and TNF-α in the oral mucosa
[32] and serum of the patients with OLP [33].
INF-γ is one of the most critical mediators of immun-
ity and inflammation and plays a pivotal role in both in-
nate and adaptive immune responses [34]. It has been
shown to promote innate immune responses by activat-
ing macrophages. Further by disrupting several anti-
inflammatory feedback loops, INF-γ also up-regulates
various proinflammatory mediators [35]. IFN-γ is known
to enhance Th1 responses by activating NK cells and
macrophages. It also promotes the specific cytotoxic im-
munity via T cell and APC interaction [36].
Moreover, IFN-γ is among the most extensively stud-
ied cytokines in OLP. Higher expression of IFN-γ has
been reported in the isolated T-cell lines from the OLP
biopsies [2, 37] and in erosive OLP lesions [3, 37]. Its ex-
pressions have been located on the CD4 + Th cells in
OLP lesions [38]. Sugerman et al. [1] suggested that the
high expression of IFN-γ at the advanced stage of OLP
development may be involved in the activation of CD8 +
T cells and help in maintaining the expression of major
histocompatibility class on the keratinocyte. The in-
creased expressions of IFN-γ in OLP influence the clin-
ical outcome and has been associated with the clinical
manifestations of OLP lesions [39].
On the other hand, in this study no significant differ-
ence in the allele or genotype frequencies of IL-6 (174G/
C) were observed between the OLP subjects and healthy
controls (Table 2). In contrast to our results some reports
have indicated an association of IL-6 (−174 (G/C) with the
OLP susceptibility. Xavier et al. [17] found a significant
higher frequency of IL-6 174 G/G genotype in a cohort of
Brazilian patients with OLP and suggested an association
with the susceptibility of OLP and involvement of this
polymorphism in the genetic basis of this disease.
Recently the IL-6 (174G/C) polymorphism has also
been significantly associated with oral precancerous
Fig. 2 Amplified DNA digested with SfaNI showing genotypes of IL-6(174G/C). Lane M: 100 bp DNA marker, Lane 1, 2, 3,5,6,7 and 8 for genotype
GC (3 bands of 198, 140 and 58 bp), Lane 4 for genotype CC (uncut DNA of 198 bp), Lane 10 for genotype GG (2 bands of 140 and 58 bp)
Fig. 3 Amplified DNA digested with Bsu36 I showing genotypes of TGF-β1 (509C/T). Lane M: 100 bp DNA marker, Lane 1, 3 and 6 for genotype
CT(3 bands of 441, 251and190bp), Lane 2 and 5 for genotype TT (uncut DNA of 441 bp), Lane 4 for genotype CC (2 bands of 251 and 190 bp)
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lesions (OPCLs) in Taiwanese patients [16]. These differ-
ences in the results can be attributed to the ethnic varia-
tions in the distribution of polymorphic variants as the
genotypes/alleles frequencies of polymorphisms are
known to vary according to race or ethnicity.
Further, we did not notice any significant difference in
the allele or genotype frequencies of TGF-β1 poly-
morphism between the OLP patients and healthy con-
trols in this study. Frequency of the T allele of TGF- β 1
(509 C/T) polymorphism in the OLP patient group was
41.67 % as compared to 50.0 % in the control group. Ge-
notypes (TT, TC, and CC) frequencies of TGF-β 1 (509
C/T) polymorphism among the patients and the healthy
controls though differed but the difference was not sta-
tistically significant (Table 3). In accordance with our re-
sults, a study from Italy also repoted no significant
difference in the allele or genotype frequencies of TGF-
β1 between the OLP subjects and healthy controls [26].
Recently Hsu et al. [16] suggested that polymorphism in
TGF-β 1 (C/T) (rs1800469) is not associated with
OPCLs but another polymorphism TGF-β 1 (C/G) at
codon 25 is associated significantly with the develop-
ment of OPCLs in Taiwanese.
TGF-β plays highly significant role in the immune sys-
tem. It regulates the IFN-γ production by NK cells. It
can help accumulate the pro-inflammatory macrophage
Table 4 Genotypes frequencies of IFN-γ (874A/T) polymorphism in different healthy populations
Population Subjects number Genotypes References
AA AT TT
Saudis 195 49 (25.13) 91 (46.66) 55 (28.21) Present study
Brazilian 186 64 (34.41) 77 (41.40) 45 (24.19) [46]
Brazilian 76 17 (22.37) 46 (60.53) 13 (17.10) [47]
Brazilian 191 60 (31.41) 34 (17.80) 97 (50.79) [48]
Canadian 91 27 (29.67) 41 (45.06) 23 (25.27) [49]
Chinese 480 212 (44.17) 201 (41.87) 67 (13.96) [50]
Chinese 97 77 (79.38) 17 (17.53) 3 (3.09) [51]
Chinese 128 101 (78.91) 26 (20.31) 1 (0.78) [52]
Egyptian 118 6 (5.08) 60 (50.85) 52 (44.07) [53]
Egyptian 106 8 (7.5) 92 (86.8) 6 (5.7) [54]
Finnish 63 23 (36.51) 31 (49.21) 9 (14.28) [55]
German 561 9 (1.60) 136 (24.24) 416 (74.15) [56]
Greek 39 5 (12.82) 23 (58.97) 11 (28.21) [57]
Indian 881 281 (31.90) 435 (49.37) 165 (18.73) [58]
Indian 374 90 (24.07) 178 (47.59) 106 (28.34) [59]
Indian 150 66 (44) 63 (42) 21 (14) [60]
Iranian 354 123 (34.75) 134 (37.85) 97 (27.40) [61]
Iranian 539 138 (25.60) 248 (46.01) 153 (28.39) [62]
Israeli 48 18 (37.5) 24 (50) 6 (12.5) [63]
Italian 140 42 (30) 66 (47.14) 32 (22.86) [26]
Italian 96 30 (31.25) 51 (53.13) 15 (15.62) [64]
Japanese 188 157 (83.51) 31 (16.49) 0 (0) [65]
Korean 201 151 (75.12) 47 (23.38) 3 (1.50) [66]
Polish 74 10 (13.51) 49 (66.22) 15 (20.27) [67]
Thai 154 92 (59.74) 53 (34.42) 9 (5.84) [68]
Thai 137 83 (60.58) 46 (33.58) 8 (5.84) [69]
Tunisian 113 33 (29.20) 47 (41.60) 33 (29.20) [70]
Turkish 40 15 (37.5) 21 (52.5) 4 (10) [71]
Turkish 71 31 (43.66) 31 (43.66) 9 (12.68) [72]
Turkish 99 16 (16.16) 56 (56.57) 27 (27.27) [73]
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(M1) to the anti-inflammatory type (M2) [40]. On the
other hand inhibition of TGF-β pathway in the lympho-
cytes contributes to the chronic inflammation in OLP
lesions [41] which is partly attributed to the over pro-
ductions of IFN-γ, leading to the blockage of the
phosphorylation of Smad3 [41]. The balance between
TGF-β and IFN-γ signaling determines the immuno-
logical status and can be a therapeutic target in OLP
patients [42]. The available literature on TGF-β 1
polymorphism is inconsistent, as some reports sup-
port the fact that the polymorphism is associated with
susceptibility to the disease while others suggest that
it may be protective [43–45].
Conclusion
It is concluded that the IFN-γ (874A/T) polymorph-
ism is associated with the susceptibility to OLP. On
the other hand the polymorphisms IL-6 (174G/C) and
TGF-β1 (509C/T) may not be associated with OLP
risk in our population, however further studies with
large sample size involving different ethnic popula-
tions should be conducted to strengthen our results.
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